Harmony Biosciences Holdings (HRMY) Gross Margin (2020 - 2026)

Harmony Biosciences Holdings has disclosed Gross Margin across 7 years of filings, most recently posting 79.33% for Q1 2026.

• Gross Margin for Q1 2026 came in at 79.33%, down 335.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 76.55% (down 179.0% YoY), and the FY2025 annual result was 77.16%, down 90.0% from the prior year.
• Gross Margin came in at 79.33% for Q1 2026 at Harmony Biosciences Holdings, up from 71.88% in the prior quarter.
• In the past five years, Gross Margin ranged from a high of 82.75% in Q1 2022 to a low of 71.88% in Q4 2025.
• The 5-year median for Gross Margin is 80.41% (2022), against an average of 79.19%.
• Across the five-year window, Gross Margin plunged 467 bps in 2023 and jumped 46 bps in 2025, its largest moves.
• Harmony Biosciences Holdings' Gross Margin stood at 79.05% in 2022, then decreased by 6 bps to 74.38% in 2023, then fell by 2 bps to 72.97% in 2024, then declined by 1 bps to 71.88% in 2025, then grew by 10 bps to 79.33% in 2026.
• The last three Gross Margin figures came in at 79.33% (Q1 2026), 71.88% (Q4 2025), and 75.09% (Q3 2025), per Business Quant data.